CA2890964C - Image analysis for breast cancer prognosis - Google Patents

Image analysis for breast cancer prognosis Download PDF

Info

Publication number
CA2890964C
CA2890964C CA2890964A CA2890964A CA2890964C CA 2890964 C CA2890964 C CA 2890964C CA 2890964 A CA2890964 A CA 2890964A CA 2890964 A CA2890964 A CA 2890964A CA 2890964 C CA2890964 C CA 2890964C
Authority
CA
Canada
Prior art keywords
score
heterogeneity
her2
breast cancer
view
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2890964A
Other languages
English (en)
French (fr)
Other versions
CA2890964A1 (en
Inventor
Srinivas Chukka
Anindya SARKAR
Crystal SCHEMP
Olcay SERTEL
Shalini Singh
Raymond Tubbs
Paul Michael WARING
Nikolaus Wick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
Cleveland Clinic Foundation
Ventana Medical Systems Inc
Original Assignee
University of Melbourne
Cleveland Clinic Foundation
Ventana Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Melbourne, Cleveland Clinic Foundation, Ventana Medical Systems Inc filed Critical University of Melbourne
Publication of CA2890964A1 publication Critical patent/CA2890964A1/en
Application granted granted Critical
Publication of CA2890964C publication Critical patent/CA2890964C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00—ICT specially adapted for the handling or processing of medical images
    • G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
CA2890964A 2012-12-28 2013-12-19 Image analysis for breast cancer prognosis Active CA2890964C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261747148P 2012-12-28 2012-12-28
US61/747,148 2012-12-28
PCT/EP2013/077295 WO2014102130A1 (en) 2012-12-28 2013-12-19 Image analysis for breast cancer prognosis

Publications (2)

Publication Number Publication Date
CA2890964A1 CA2890964A1 (en) 2014-07-03
CA2890964C true CA2890964C (en) 2023-07-25

Family

ID=49917058

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2890964A Active CA2890964C (en) 2012-12-28 2013-12-19 Image analysis for breast cancer prognosis

Country Status (8)

Country Link
US (2) US11211167B2 (enExample)
EP (1) EP2939026B1 (enExample)
JP (1) JP6405319B2 (enExample)
AU (1) AU2013369439B2 (enExample)
CA (1) CA2890964C (enExample)
DK (1) DK2939026T3 (enExample)
ES (1) ES2639559T3 (enExample)
WO (1) WO2014102130A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2564200B8 (en) 2010-04-27 2019-10-02 The Regents of The University of California Cancer biomarkers and methods of use thereof
EP2965078A4 (en) * 2013-03-06 2016-11-09 Obi Holdings Inc MOLECULAR IMAGING AND RELATED METHODS
WO2015189264A1 (en) 2014-06-10 2015-12-17 Ventana Medical Systems, Inc. Predicting breast cancer recurrence directly from image features computed from digitized immunohistopathology tissue slides
WO2016087592A1 (en) 2014-12-03 2016-06-09 Ventana Medical Systems, Inc. Systems and methods for early-stage cancer prognosis
US9953133B2 (en) 2015-06-03 2018-04-24 General Electric Company Biological data annotation and visualization
US10672505B2 (en) 2015-06-03 2020-06-02 General Electric Company Biological data annotation and visualization
US9613254B1 (en) 2015-09-30 2017-04-04 General Electric Company Quantitative in situ characterization of heterogeneity in biological samples
US20170234874A1 (en) * 2015-10-07 2017-08-17 Clearbridge Biophotonics Pte Ltd. Integrated visual morphology and cell protein expression using resonance-light scattering
EP4220164B1 (en) * 2016-12-19 2024-08-21 Ventana Medical Systems, Inc. Methods and systems for quantitative immunohistochemistry
WO2018219818A1 (en) * 2017-06-02 2018-12-06 Koninklijke Philips N.V. Quantified aspects of lesions in medical images
CN107271671A (zh) * 2017-06-05 2017-10-20 龚畅 一种预测er（+）乳腺癌新辅助化疗效果的试剂盒和系统
US10586376B2 (en) * 2017-06-13 2020-03-10 Optrascan, Inc. Automated method of predicting efficacy of immunotherapy approaches
RU2664671C1 (ru) * 2017-07-28 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ прогноза рака молочной железы
EP3721406B1 (en) 2017-12-05 2024-01-24 Ventana Medical Systems, Inc. Method of computing tumor spatial and inter-marker heterogeneity
US11568657B2 (en) 2017-12-06 2023-01-31 Ventana Medical Systems, Inc. Method of storing and retrieving digital pathology analysis results
EP3721372A1 (en) 2017-12-06 2020-10-14 Ventana Medical Systems, Inc. Method of storing and retrieving digital pathology analysis results
EP3721373B1 (en) 2017-12-07 2025-03-05 Ventana Medical Systems, Inc. Deep-learning systems and methods for joint cell and region classification in biological images
WO2019121564A2 (en) 2017-12-24 2019-06-27 Ventana Medical Systems, Inc. Computational pathology approach for retrospective analysis of tissue-based companion diagnostic driven clinical trial studies
US11621058B2 (en) * 2018-02-08 2023-04-04 Ohio State Innovation Foundation Synthetic IHC-stained digital sides generated using artificial neural networks
WO2019197509A1 (en) 2018-04-13 2019-10-17 Ventana Medical Systems, Inc. Systems for cell shape estimation
WO2020023213A1 (en) 2018-07-27 2020-01-30 Ventana Medical Systems, Inc. Systems for automated in situ hybridization analysis
EP3844771B1 (en) 2018-08-31 2026-07-08 Ventana Medical Systems, Inc. Contextually adaptive digital pathology interface
WO2020056338A1 (en) * 2018-09-14 2020-03-19 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
EP3867803A1 (en) 2018-10-15 2021-08-25 Ventana Medical Systems, Inc. Systems and methods for cell classification
EP3897360B1 (en) * 2018-12-19 2026-03-04 University of Pittsburgh - of the Commonwealth System of Higher Education Computational systems pathology spatial analysis platform for in situ or in vitro multi-parameter cellular and subcellular imaging data
JP7227389B2 (ja) 2019-02-13 2023-02-21 ベンタナ メディカル システムズ， インコーポレイテッド マルチチャネル画像における自己蛍光の寄与を算出するシステムおよび方法
JP7593112B2 (ja) * 2019-02-15 2024-12-03 コニカミノルタ株式会社 情報提供方法、情報提供装置及びプログラム
US11726757B2 (en) * 2019-08-14 2023-08-15 Nvidia Corporation Processor for performing dynamic programming according to an instruction, and a method for configuring a processor for dynamic programming via an instruction
EP4022286A1 (en) 2019-08-28 2022-07-06 Ventana Medical Systems, Inc. Label-free assessment of biomarker expression with vibrational spectroscopy
WO2021050567A1 (en) 2019-09-09 2021-03-18 PAIGE.AI, Inc. Systems and methods for processing images of slides to infer biomarkers
CN110853022B (zh) 2019-11-14 2020-11-06 腾讯科技（深圳）有限公司 病理切片图像的处理方法、装置、系统及存储介质
EP4091135A1 (en) 2020-01-19 2022-11-23 Ventana Medical Systems, Inc. Non-tumor segmentation to support tumor detection and analysis
CN115088022A (zh) 2020-02-11 2022-09-20 文塔纳医疗系统公司 用于训练机器学习算法和维护患者隐私的联邦学习系统
WO2021183769A1 (en) * 2020-03-11 2021-09-16 Biosyntagma, Inc. Method for predicting disease state, therapeutic response, and outcomes by spatial biomarkers
CN115552534A (zh) * 2020-03-18 2022-12-30 赛诺菲 用于预测表达水平的系统和方法
AU2021325900A1 (en) 2020-08-13 2023-04-20 PAIGE.AI, Inc. Systems and methods to process electronic images for continuous biomarker prediction
DE102020211271A1 (de) * 2020-09-08 2022-03-10 Siemens Healthcare Gmbh Erzeugung eines Biomarkers quantifizierend eine räumliche Homogenität einer medizinischen Parameterkarte
WO2022066512A1 (en) * 2020-09-22 2022-03-31 Ventana Medical Systems, Inc. Prediction of response to epidermal growth factor receptor-directed therapies using epiregulin and amphiregulin
CN112801939B (zh) * 2020-12-31 2022-07-22 杭州迪英加科技有限公司 一种用于提高病理图像ki67指标准确性的方法
WO2022264545A1 (ja) * 2021-06-17 2022-12-22 コニカミノルタ株式会社 定量方法および標識方法
CN113970638B (zh) * 2021-10-24 2023-02-03 清华大学 确定胃癌极早期发生风险及评估胃癌前病变进展风险的分子标志及其在诊断试剂盒中的应用
JP2025526652A (ja) * 2022-08-08 2025-08-15 ヴェンタナ メディカル システムズ， インク． デジタル化された病理スライドの定量化のためのシステムおよび方法
WO2024178422A1 (en) * 2023-02-24 2024-08-29 Ohio State Innovation Foundation Novel image-based metrics of her2 heterogeneity
WO2024259271A2 (en) * 2023-06-15 2024-12-19 New York University Systems, methods and computer-accessible medium for determining and/or analysing cancer outcome(s) and/or treatment responses
WO2025014787A1 (en) * 2023-07-07 2025-01-16 Ventana Medical Systems, Inc. Brightfield triplex immunohistochemistry assay for evaluating the colocalization of the er, pr, and ki-67 biomarkers in cells
WO2025106811A1 (en) * 2023-11-15 2025-05-22 4D Path Inc. Systems and methods for image-based disease characterization
KR20250156974A (ko) 2024-04-26 2025-11-04 사회복지법인 삼성생명공익재단 딥러닝 모델을 이용한 종양 미세환경 예측 방법 및 분석장치
TWI900356B (zh) * 2024-12-03 2025-10-01 國立中央大學 建立組織微陣列影像模型以及使用該模型判定組織型態的方法
CN120544841A (zh) * 2025-05-12 2025-08-26 中国人民解放军总医院 一种融合多模态特征预测乳腺癌分类的处理方法和装置

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444487A (en) 1979-07-02 1984-04-24 Xerox Corporation Multiple-flash fuser
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
EP0256654B1 (en) 1986-07-07 1996-09-18 Centocor, Inc. Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
GB0229734D0 (en) 2002-12-23 2003-01-29 Qinetiq Ltd Grading oestrogen and progesterone receptors expression
US20050136549A1 (en) 2003-10-30 2005-06-23 Bioimagene, Inc. Method and system for automatically determining diagnostic saliency of digital images
US8787651B2 (en) * 2010-09-28 2014-07-22 Flagship Biosciences, LLC Methods for feature analysis on consecutive tissue sections
US9286672B2 (en) * 2012-01-10 2016-03-15 Rutgers, The State University Of New Jersey Integrated multivariate image-based method for disease outcome predicition
JP2013200287A (ja) 2012-03-26 2013-10-03 Kawasaki Gakuen Ｋｉ−６７インデックス算定二重染色法を用いた陽性率測定方法

Also Published As

Publication number Publication date
ES2639559T3 (es) 2017-10-27
US20220051804A1 (en) 2022-02-17
JP2016503167A (ja) 2016-02-01
CA2890964A1 (en) 2014-07-03
JP6405319B2 (ja) 2018-10-17
US20150347702A1 (en) 2015-12-03
WO2014102130A1 (en) 2014-07-03
AU2013369439B2 (en) 2019-01-17
EP2939026B1 (en) 2017-07-05
DK2939026T3 (en) 2017-09-11
AU2013369439A1 (en) 2015-05-28
EP2939026A1 (en) 2015-11-04
US11211167B2 (en) 2021-12-28

Similar Documents

Publication Publication Date Title
US20220051804A1 (en) Image Analysis for Breast Cancer Prognosis
Wolff et al. Human epidermal growth factor receptor 2 testing in breast cancer
Lloyd et al. Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it?
Brügmann et al. Digital image analysis of membrane connectivity is a robust measure of HER2 immunostains
CN112789684B (zh) 用于预测对pd-1轴导向疗法的应答的方法和系统
KR102179848B1 (ko) 종양 조직 중 면역 세포를 정량화하는 방법 및 이의 사용
Niikura et al. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups
Holten-Rossing et al. Optimizing HER2 assessment in breast cancer: application of automated image analysis
US20110111435A1 (en) Detecting Cell Surface Markers
US20130338016A1 (en) Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern Analysis
Sun et al. Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer
Ibrahim et al. Improving mitotic cell counting accuracy and efficiency using phosphohistone‐H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading
Zbytek et al. Nottingham-defined mitotic score: comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype DX recurrence score
Kim et al. Risk factors associated with discordant Ki-67 levels between preoperative biopsy and postoperative surgical specimens in breast cancers
Qi et al. Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients
Feng et al. Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer
JP2015525358A (ja) 組織切片中の単一細胞におけるマーカー定量
Cho et al. The long-term prognostic performance of Ki-67 in primary operable breast cancer and evaluation of its optimal cutoff value
Singh et al. Analytical validation of quantitative immunohistochemical assays of tumor infiltrating lymphocyte biomarkers
JP7855525B2 (ja) 腫瘍試料中のｅｇｆｒおよびｅｇｆｒリガンドの発現を評価するための組織化学的システムおよび方法
Ali et al. Mast cells in the microenvironment of hepatocellular carcinoma confer favorable prognosis: a retrospective study using QuPath image analysis software
Liu et al. A comparative performance analysis of multispectral and rgb imaging on her2 status evaluation for the prediction of breast cancer prognosis
Nassar et al. Trainable immunohistochemical HER2/neu image analysis: a multisite performance study using 260 breast tissue specimens
Wang et al. Laboratory validation studies in Ki-67 digital image analysis of breast carcinoma: a pathway to routine quality assurance
Jing et al. Validity and reliability of Ki-67 assessment in oestrogen receptor positive breast cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181204

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241209

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251121